From: Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)
Patient no. | Age (years) | Gender | Diagnosis, stagea | Paraprotein type | Bence-Jones | Prior treatment | Statusb | Melphalan dose (mg/kg) |
---|---|---|---|---|---|---|---|---|
SC001 | 61 | M | Multiple myeloma, III-A | IgG κ | Not present | VAD, CAD | Partial response | 3.92 |
SC002 | 62 | F | Multiple myeloma, III-A | IgG κ | Present | VAD, CAD | Progressive disease | 5.61 |
SC003 | 50 | M | Multiple myeloma, III-A | Light chain κ | Present | VAD, CAD | Minimal response | 5.19 |
SC004 | 55 | M | Multiple myeloma, III-A | IgG κ, light chain κ | Not present | VAD, CAD | Partial response | 5.13 |
SC005 | 45 | M | Multiple myeloma, III-A | Light chain κ | Present | PAD, CAD | Partial response | 6.25 |
SC006 | 39 | M | Multiple myeloma, III-B | IgG κ | Not present | VAD, CAD | Minimal response | 4.37 |
SC007 | 54 | M | Multiple myeloma, II-A | IgG κ | Not present | Thalidomide, dexamethasone, CAD | Stable disease | 5.07 |
SC008 | 61 | M | Lymphoplasmocytic lymphoma, IV-A | IgG κ, light chain κ | Present | VAD, CAD | Minimal response | 5.13 |